View all newsletters
Receive our newsletter - data, insights and analysis delivered to you
  1. News
December 15, 2017

Deals this week: Shanghai Shyndec Pharmaceutical, Aprecia Pharmaceuticals, Daiichi Sankyo Company

Shanghai Shyndec Pharmaceutical plans to raise CNY2.03bn ($307.41m) through the private placement of convertible bonds.

Shanghai Shyndec Pharmaceutical plans to raise CNY2.03bn ($307.41m) through the private placement of convertible bonds.

The bonds have a maturity period of six years from the issued date.

Headquartered in China, Shanghai Shyndec is a manufacturer of active pharmaceutical ingredients (APIs), chemical raw materials, and finished drug products.

Aprecia Pharmaceuticals has collaborated with Cycle Pharmaceuticals to develop and commercialise ZipDose 3D-printed orphan drugs using the former’s FDA-approved 3DP ZipDose technology platform.

Based in the US, Aprecia Pharmaceuticals is a drug delivery technology company, while Cycle Pharmaceuticals is a UK-based pharmaceutical company.

“Aprecia Pharmaceuticals has collaborated with Cycle Pharmaceuticals to develop and commercialise ZipDose 3D-printed orphan drugs using the former’s FDA-approved 3DP ZipDose technology platform.”

Japanese pharmaceutical products manufacturer Daiichi Sankyo Company and Puma Biotechnology have signed a pre-clinical research agreement with Memorial Sloan Kettering Cancer Center (MSK).

Daiichi Sankyo’s investigational drug conjugate DS-8201 and Puma Biotech’s tyrosine kinase inhibitor neratinib (NERLYNX) will be investigated in HER2-mutated or HER2-positive solid tumours, as part of the agreement.

Veru has acquired the global rights for oral granule formulation solifenacin from Camargo Pharmaceuticals Services.

Solifenacin is the API in VESIcare, a drug used for treating overactive bladder in men and women.

The acquisition allows Viru to enhance its novel urology drugs portfolio.

Related Companies

NEWSLETTER Sign up Tick the boxes of the newsletters you would like to receive. A weekly roundup of the latest news and analysis, sent every Friday. The pharmaceutical industry's most comprehensive news and information delivered every month.
I consent to GlobalData UK Limited collecting my details provided via this form in accordance with the Privacy Policy
SUBSCRIBED

THANK YOU

Thank you for subscribing to Pharmaceutical Technology